New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
05:19 EDTCORTCorcept Therapeutics downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray downgraded Corcept Therapeutics to Underweight citing the positive FDA panel vote for Novartisís Signifor, a direct competitor to Corcept's Korlym. The firm lowered its price target for shares to $1.10 from $3.
News For CORT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2016
16:11 EDTCORTCorcept Therapeutics sees FY16 revenue $76M-$81M, consensus $83.33M
Subscribe for More Information
16:10 EDTCORTCorcept Therapeutics reports preliminary Q4 GAAP EPS 1c, consensus (2c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use